Creso Pharma Limited (ASX: CPH) - Positioning For The Expanding Cannabis Market
Equity Research Coverage Reports
CPH will develop, register and commercialise, in association with licenced partners, animal health and human food supplements manufactured from cannabis. The company currently generates a modest income from sale of products. These products have a low concentration of the hallucinogenic compound THC, but high concentrations of the other medicinal compounds found in the cannabis plant.
Access to this Web site is granted by NRA Capital Pte. Ltd. strictly on the terms
and subject to the conditions set out hereunder. By entering into the Web Site,
Subscriber is deemed to have accepted and agreed to be bound by the
terms and conditions
set out hereunder.